Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Deyo, D. Cherkin, D. Cherkin, M. Ciol (1992)
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.Journal of clinical epidemiology, 45 6
Bengt Danielsson, J. Collin, Gudrun Bergman, N. Borg, P. Salmi, J. Fastbom (2016)
Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study.British journal of clinical pharmacology, 81 4
Silvia Priori, Carina Blomström-Lundqvist, Andrea Mazzanti, Nico Blom, Martin Borggrefe, John Camm, Perry Elliott, Donna Fitzsimons, R. Hatala, Gerhard Hindricks, Paulus Kirchhof, Keld Kjeldsen, Karl-Heinz Kuck, A. Hernández–Madrid, N. Nikolaou, T. Norekvål, Christian Spaulding, D. Veldhuisen (2016)
2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.Revista espanola de cardiologia, 69 2
A. Glassman, C. O’Connor, R. Califf, K. Swedberg, P. Schwartz, J. Bigger, K. Krishnan, Louis Zyl, J. Swenson, M. Finkel, Charles Landau, P. Shapiro, C. Pepine, J. Mardekian, W. Harrison, D. Barton, Michael Mclvor (2002)
Sertraline treatment of major depression in patients with acute MI or unstable anginaEuropean Neuropsychopharmacology, 12
S. Priori, A. Wilde, M. Horie, Yongkeun Cho, E. Behr, C. Berul, N. Blom, J. Brugada, C. Chiang, H. Huikuri, P. Kannankeril, A. Krahn, A. Leenhardt, A. Moss, P. Schwartz, W. Shimizu, G. Tomaselli, C. Tracy (2013)
HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.Heart rhythm, 10 12
D. Roden (2004)
Drug-induced prolongation of the QT interval.The New England journal of medicine, 350 10
G. Rao, J. Mann, A. Shoaibi, Charles Bennett, G. Nahhas, S. Sutton, Sony Jacob, S. Strayer (2014)
Azithromycin and Levofloxacin Use and Increased Risk of Cardiac Arrhythmia and DeathThe Annals of Family Medicine, 12
Priori (2015)
2793Eur Heart J, 36
Kristina Haugaa, J. Bos, R. Tarrell, B. Morlan, Pedro Caraballo, Michael Ackerman (2013)
Institution-wide QT alert system identifies patients with a high risk of mortality.Mayo Clinic proceedings, 88 4
T. Hintsa, L. Keltikangas-Järvinen, S. Puttonen, N. Ravaja, L. Toivonen, K. Kontula, H. Swan (2009)
Depressive symptoms in the congenital long QT syndromeAnnals of Medicine, 41
P. Weeke, A. Jensen, F. Folke, G. Gislason, J. Olesen, C. Andersson, E. Fosbøl, J. Larsen, F. Lippert, S. Nielsen, T. Gerds, P. Andersen, Jørgen Kanters, H. Poulsen, S. Pehrson, L. Køber, C. Torp-Pedersen (2012)
Antidepressant Use and Risk of Out‐of‐Hospital Cardiac Arrest: A Nationwide Case–Time–Control StudyClinical Pharmacology & Therapeutics, 92
SG Priori, C Blomstrom-Lundqvist, A Mazzanti, N Blom, M Borggrefe, J Camm, PM Elliott, D Fitzsimons, R Hatala, G Hindricks, P Kirchhof, K Kjeldsen, KH Kuck, A Hernandez-Madrid, N Nikolaou, TM Norekval, C Spaulding, DJ. Van Veldhuisen (2015)
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)Eur Heart J, 36
C. Gibbs, J. Thalamus, K. Heldal, Ø. Holla, K. Haugaa, J. Hysing (2018)
Predictors of mortality in high-risk patients with QT prolongation in a community hospital.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 20 FI1
M. Nuttall, J. Meulen, M. Emberton (2006)
Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery.Journal of clinical epidemiology, 59 3
J. Theilade, Jørgen Kanters, F. Henriksen, Michael Gilså-Hansen, J. Svendsen, O. Eschen, E. Toft, J. Reimers, A. Tybjærg‐Hansen, M. Christiansen, H. Jensen, H. Bundgaard (2013)
Cascade Screening in Families with Inherited Cardiac Diseases Driven by Cardiologists: Feasibility and Nationwide Outcome in Long QT SyndromeCardiology, 126
H. Svanström, B. Pasternak, A. Hviid (2014)
Use of clarithromycin and roxithromycin and risk of cardiac death: cohort studyThe BMJ, 349
Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses
AimsIt is Class I recommendation that congenital long QT syndrome (cLQTS) patients should avoid drugs that can cause torsades de pointes (TdP). We determined use of TdP risk drugs after cLQTS diagnosis and associated risk of ventricular arrhythmia and all-cause mortality.Methods and resultsCongenital long QT syndrome patients (1995–2015) were identified from four inherited cardiac disease clinics in Denmark. Individual-level linkage of nation-wide registries was performed to determine TdP risk drugs usage (www.crediblemeds.org) and associated risk of ventricular arrhythmias and all-cause mortality. Risk analyses were performed using Cox-hazards analyses. During follow-up, 167/279 (60%) cLQTS patients were treated with a TdP risk drug after diagnosis. Most common TdP risk drugs were antibiotics (34.1%), proton-pump inhibitors (15.0%), antidepressants (12.0%), and antifungals (10.2%). Treatment with a TdP risk drug decreased 1 year after diagnosis compared with 1 year before (28.4% and 23.2%, respectively, P < 0.001). Five years after diagnosis, 33.5% were in treatment (P < 0.001). Risk factors for TdP risk drug treatment were age at diagnosis (5-year increment) [hazard ratio (HR) = 1.07, confidence interval (CI) 1.03–1.11] and previous TdP risk drug treatment (HR = 2.57, CI 1.83–3.61). During follow-up, nine patients were admitted with ventricular arrhythmia (three were in treatment with a TdP risk drug). Eight patients died (four were in treatment with a TdP risk drug). No significant association between TdP risk drug use and ventricular arrhythmias or all-cause mortality was found (P = 0.53 and P = 0.93, respectively), but events were few.ConclusionTorsades de pointes risk drug usage was common among cLQTS patients after time of diagnosis and increased over time. A critical need for more awareness in prescribing patterns for this high-risk patient group is needed.
European Heart Journal – Oxford University Press
Published: May 11, 2019
Keywords: Congenital long QT syndrome; Torsades de pointes; Ventricular tachycardia; Ventricular arrhythmia; Pharmacotherapy; Adverse drug events
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.